Drugs Made In Amer Acqutn Corp Financials
This page shows Drugs Made In Amer Acqutn Corp (DMAA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Reported profit masks a transaction-driven balance sheet: operating activity used cash while liquidity remained extremely thin.
The combination of$5.9M net income and an-$2.8M operating loss shows that reported earnings were driven by something other than the core cost base. A$231.7M financing inflow nearly matched the-$231.2M investing outflow, indicating that the year's scale was set by balance-sheet transactions rather than self-funded business activity.
With only
The balance sheet is large relative to day-to-day liquidity:
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Drugs Made In Amer Acqutn Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Drugs Made In Amer Acqutn Corp's current ratio of 0.03 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
For every $1 of reported earnings, Drugs Made In Amer Acqutn Corp generates $-0.09 in operating cash flow (-$539K OCF vs $5.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Drugs Made In Amer Acqutn Corp reported $5.9M in net income in fiscal year 2025.
Cash & Balance Sheet
Drugs Made In Amer Acqutn Corp held $6K in cash against $0 in long-term debt as of fiscal year 2025.
Drugs Made In Amer Acqutn Corp had 34M shares outstanding in fiscal year 2025.
Margins & Returns
Capital Allocation
DMAA Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $143K | N/A | $264K+99.9% | $132K-60.1% | $331K | N/A | $145K |
| Operating Income | -$143K | N/A | -$264K-99.9% | -$132K+60.1% | -$331K | N/A | -$145K |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | $2.0M | N/A | $2.2M-4.5% | $2.3M+82.4% | $1.3M | N/A | -$145K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
DMAA Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|
| Total Assets | $242.0M+0.9% | $239.9M+1.0% | $237.6M+1.0% | $235.2M+1.0% | $232.8M+42165.1% | $551K | N/A |
| Current Assets | $15K+22.1% | $12K-56.8% | $28K-43.3% | $50K-30.0% | $71K+1322.9% | $5K | N/A |
| Cash & Equivalents | $15K+142.6% | $6K+755.9% | $717-12.8% | $822-10.9% | $923-31.7% | $1K-35.5% | $2K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $249.4M+0.9% | $247.2M+0.9% | $245.0M+1.1% | $242.4M+1.0% | $240.0M+30061.1% | $796K | N/A |
| Current Liabilities | $492K+30.8% | $376K-17.6% | $457K+51.5% | $301K-13.2% | $347K-56.3% | $796K | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$7.4M-1.6% | -$7.3M+0.9% | -$7.3M-2.5% | -$7.2M+0.3% | -$7.2M-2831.0% | -$245K-48.5% | -$165K |
| Retained Earnings | -$7.4M-1.6% | -$7.3M-8.1% | -$6.7M-4.1% | -$6.5M-2.1% | -$6.3M-2160.2% | -$280K | N/A |
DMAA Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$91K+27.1% | -$125K-123.1% | -$56K+47.4% | -$107K+57.5% | -$251K-236922.6% | -$106+99.9% | -$172K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | $0 | $0 | $0+100.0% | -$231.2M | N/A | N/A |
| Financing Cash Flow | $100K-23.4% | $131K+133.2% | $56K-47.4% | $107K-100.0% | $231.4M+36269820.4% | -$638-100.4% | $174K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
DMAA Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 0.8% | N/A | 0.9%-0.1pp | 1.0%+0.4pp | 0.5% | N/A | N/A |
| Current Ratio | 0.030.0 | 0.03-0.0 | 0.06-0.1 | 0.17-0.0 | 0.20+0.2 | 0.01 | N/A |
| Debt-to-Equity | -33.81+0.2 | -34.03-0.6 | -33.43+0.5 | -33.89-0.4 | -33.44-30.2 | -3.25 | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$7.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Frequently Asked Questions
Is Drugs Made In Amer Acqutn Corp profitable?
Yes, Drugs Made In Amer Acqutn Corp (DMAA) reported a net income of $5.9M in fiscal year 2025.
What is Drugs Made In Amer Acqutn Corp's operating cash flow?
Drugs Made In Amer Acqutn Corp (DMAA) generated -$539K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Drugs Made In Amer Acqutn Corp's total assets?
Drugs Made In Amer Acqutn Corp (DMAA) had $239.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Drugs Made In Amer Acqutn Corp's current ratio?
Drugs Made In Amer Acqutn Corp (DMAA) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Drugs Made In Amer Acqutn Corp's debt-to-equity ratio?
Drugs Made In Amer Acqutn Corp (DMAA) had a debt-to-equity ratio of -34.03 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Drugs Made In Amer Acqutn Corp's return on assets (ROA)?
Drugs Made In Amer Acqutn Corp (DMAA) had a return on assets of 2.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Drugs Made In Amer Acqutn Corp's cash runway?
Based on fiscal year 2025 data, Drugs Made In Amer Acqutn Corp (DMAA) had $6K in cash against an annual operating cash burn of $539K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Drugs Made In Amer Acqutn Corp's debt-to-equity ratio negative or unusual?
Drugs Made In Amer Acqutn Corp (DMAA) has negative shareholder equity of -$7.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Are Drugs Made In Amer Acqutn Corp's earnings high quality?
Drugs Made In Amer Acqutn Corp (DMAA) has an earnings quality ratio of -0.09x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Drugs Made In Amer Acqutn Corp?
Drugs Made In Amer Acqutn Corp (DMAA) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.